Publications by authors named "Jacob Pontoppidan"
Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial.
Am Heart J
January 2022
Background: The prevalence of atrial fibrillation (AF) is increasing globally, which is a major clinical and public health concern due to the 5-fold increased risk of stroke. Oral anticoagulation with novel oral anticoagulants (NOACs) is the current primary option for stroke prevention in patients with AF, although it increases the risk of major bleeding. Patients with prior ischemic cerebrovascular events are at particularly high risk of both recurrent ischemic events and major bleeding.
View Article and Find Full Text PDFAims: To evaluate the clinical outcome of pulmonary vein isolation (PVI) in radiofrequency ablation of atrial fibrillation (AF) comparing a strategy using Ablation Index (AI) and lesion contiguity with Contact Force (CF) only.
Methods: In a single-center retrospective design, we included 479 patients with AF (n=341 (71.2%) paroxysmal AF (PAF) and n=138 (28.
Smartphone-based ECG monitor devices are a new promising tool for rhythm detection in patients with palpitations. We present a case where a young patient with infrequent arrhythmia episodes was diagnosed with atrial fibrillation using this novel smartphone-based event recorder.
View Article and Find Full Text PDFQuality of life (QoL) is a very important endpoint in trials reporting the efficacy of catheter ablation in patients with atrial fibrillation (AF). It has been shown that AF ablation significantly improves the QoL, but recent studies question the usefulness of the most used generic QoL instrument in AF patients. The complexity of the disease makes it mandatory to employ disease specific instruments in the assessment of QoL.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the recurrence of atrial fibrillation (AF) and flutter (AFL) after a specific treatment called circumferential pulmonary vein ablation (CPVA), using long-term Holter monitoring and analyzing quality of life (QoL).
- 149 patients were monitored with 7-day Holter recordings for up to 12 months post-CPVA, categorizing their arrhythmia episodes and using SF-36 questionnaires to evaluate QoL changes in relation to symptom presence.
- Results showed that 44% of patients had asymptomatic arrhythmia after a year, with a notable improvement in the QoL physical scores for those with asymptomatic recurrences compared to those who were symptomatic, indicating the need
Article Synopsis
- The study compares two main methods of radiofrequency ablation for treating atrial fibrillation: segmental pulmonary vein isolation (SPVI) and circumferential pulmonary vein isolation (CPVI).
- Results show that 73% of patients were symptom-free after CPVI, while only 25% were symptom-free after SPVI.
- The findings suggest that CPVI is a safer and more effective treatment for patients with severe symptoms and drug-resistant AF when performed by experienced specialists.